ClinicalTrials.gg
CompletedNCT03388190METIMMOXUpdated Feb 13, 2026Results posted

METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin

A Phase 2 interventional study of Nivolumab and FLOX in Colorectal Cancer Metastatic, sponsored by University Hospital, Akershus. Completed at 5 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Primary conditionNeoplasm MetastasisRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasm Metastasis
Why
  1. The study's title name Neoplasm Metastasis, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Akershus · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies testing nivolumab in Neoplasm Metastasis — 6 open to participants now, 16 under way, none of them phase 3. Nivolumab · Neoplasm Metastasis.

Enrollment
10th of 43
80 · median 48
Started
2018
with 4 others
Phase 2
30 of 43
4 open now
Registered
13th of 43
by date

Among the 43 studies testing nivolumab in Neoplasm Metastasis, this one is the 10th largest by enrollment, is one of 5 that started in 2018, is one of 30 in phase 2, and was the 13th registered.

Neoplasm Metastasis

4,045 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

6 of the 43 studies testing nivolumab in Neoplasm Metastasis are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing nivolumab in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This study aims to determine the efficacy, safety, and tolerability of the sequential addition of immune-modulating therapy to standard-of-care therapy of microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC).

Read the detailed description

Hypothesis: Patients with MSS/pMMR-mCRC harbor tumor that can be transformed into an immunogenic disease by short-course oxaliplatin-based therapy, and may thereby benefit from the addition of immune-modulating therapy to improve outcome of the current oxaliplatin-based standard-of-care.

Primary objective: To determine progression-free survival (PFS), in terms of failure of treatment strategy, of sequential treatment with the Nordic FLOX (5-Fluorouracil, oxaliplatin and leucovorin) regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen in previously untreated MSS/pMMR-mCRC.

Secondary objectives: To determine safety and tolerability of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen. To monitor and compare quality-of-life (QoL) alterations during therapy courses.

03

Conditions studied

  • Colorectal Cancer Metastatic

Browse trials for

Keywords

  • Colorectal
  • Cancer
  • Neoplasm
  • Nivolumab
  • Fluorouracil
  • Metastatic
  • Oxaliplatin
  • Leucovorin
04

In context

Neoplasm Metastasis Reclassified

4,045 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

This study's enrollment of 80 is above the median of 50 across 3,273 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

University Hospital, Akershus is the lead sponsor of 125 studies on the registry; 27 are open to participants now.

Compared within Neoplasm Metastasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has verified CRC adenocarcinoma (also comprising the mucinous adenocarcinoma and signet-ring cell carcinoma entities).
  • Patient is ambulatory with (ECOG) performance status 0 or 1.
  • Patient has radiologically measurable disease.
  • Patient has an intra-abdominal metastatic lesion that can be biopsied.
  • Patient has not had previous systemic therapy for the metastatic disease.
  • Patient is eligible for the Nordic FLOX regimen.
  • Patient has the following laboratory values, as measured in serum/plasma within 14 days prior to study entry, indicative of adequate organ function:

    • at least 10.0 g/dL.
    • Neutrophils at least 1.5 x109/L (without current use of colony-stimulating factors).
    • at least 100 x109/L.
    • C-reactive protein (CRP) less than 60 mg/L.
    • (AST)/Alanine transaminase (ALT) no higher than 2xULN when patient does not have metastatic disease in the liver or no higher than 5xULN when patient has metastatic disease in the liver.
    • no higher than 1.5x when patient does not have metastatic disease in the liver or no higher than 2x upper limit of normal (ULN) when patient has metastatic disease in the liver.
    • Albumin no lower than 30 g/L.
    • (INR) within normal level.
    • Creatinine no higher than 1.5x ULN.
  • Woman of (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
  • WOCBP will use an adequate method to avoid pregnancy for a period of 26 weeks (which includes the required 30 days plus the time required for nivolumab to undergo five half-lives) after the last therapy dose, irrespective of study arm.
  • Woman is not breastfeeding.
  • Male who is sexually active with WOCBP must agree to follow instructions for method(s) of for a period of 26 weeks (which includes the required time to ensure duration of sperm turnover plus the time required for the drugs to undergo five half-lives) after the last therapy dose, irrespective of study arm.
  • Signed form (ICF) and expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to International Conference on Harmonization (ICH) - Good Clinical Practice (GCP) and national/local regulations.

Exclusion criteria

Exclusion Criteria:

  • Patient has initially resectable disease for which therapy is deemed superfluous.
  • Patient does not consent to sampling.
  • Patient has metastatic disease to lungs as the sole site.
  • Patient has untreated or symptomatic (patient must be symptom-free without the use of ).
  • Patient experiences a period of less than 6 months since discontinuation of adjuvant oxaliplatin-containing chemotherapy.
  • Patient is ineligible for full chemotherapy doses (100% doses) at start of study treatment.
  • Patient has had radiation therapy against the only within 4 weeks of start of study treatment.
  • Patient has any medical condition treated with anticoagulant medication that cannot be replaced by low molecular weight heparin during active study treatment.
  • Patient has a nervous system disorder worse than (CTCAE) grade 1.
  • Patient has any medical condition that will preclude him/her from cancer immune-modulating therapy, such as:

    • Active or chronic or .
    • Known history of or acquired immunodeficiency-related illnesses.
    • Diagnosis of immunodeficiency or medical condition requiring systemic steroids or other forms of therapy.
    • disease that has required systemic therapy within the past 2 years.
    • Receipt of within 30 days prior to study entry or within 30 days of receiving study therapy.
    • Active infection or chronic infection requiring chronic suppressive antibiotics.
    • Known history of previous diagnosis of tuberculosis.
  • Patient with current or prior use of immunosuppressive medication within 28 days before the first dose of study therapy, with the exceptions of intranasal corticosteroids or systemic corticosteroids at physiological doses that do not exceed 10mg/day of prednisone or an equivalent corticosteroid.
  • Patient has any medical condition or needs to use medication, as listed in the Summary of Product characteristics (SmPC) of each Medical Product (IMP), that will preclude him/her from receiving treatment with IMP, such as:

    • Pernicious anemia or anemias due to vitamin B12 deficiency (SmPC-listed for folinic acid).
    • Other SmPC-listed contraindications for folinic acid and SmPC-listed contraindications for the other IMPs are covered by other exclusion criteria.
  • Patient has undergone treatment with any IMP that may interfere with the study treatment within 4 weeks prior to first administration of study drug.
  • Patient has known to any of the study IMP components.
  • Patient has performance status 2 or worse.
  • Patient has serum/plasma CRP of 60 mg/L or higher.
  • Patient does not meet the following requirements at baseline: adequate bone marrow function without current use of colony-stimulating factors (minimum values of neutrophils 1.5 x109/L, 100 x109/L, 10 g/dL), adequate liver function (maximum values of /ALT 5x and 2x ULN; albumin value of 30 g/L or higher; within normal level), adequate renal function (maximum creatinine value of 1.5x ULN).
  • Patient has history of other prior , with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB ( clinically visible lesion confined to cervix uteri), stage I prostate cancer considered not necessary to treat, and another malignancy that was treated with curative intent more than 5 years ago and has not later.
  • Patient has significant cardiac, pulmonary, or other medical illness that would limit activity of daily life or survival.
  • Patient is pregnant or breastfeeding.
  • Patient has any other reason, in the opinion of Clinical Investigator, not to participate in the study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Control Arm

    The control arm will consist of intermittent treatment with the Nordic FLOX regimen in terms of 8 cycles before break until disease progression, when therapy is reintroduced and administered for another 8 cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first.

    Drug: FLOX

  • Experimental
    Experimental Arm

    The experimental arm will consist of repeat 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 8 individual cycles before break until disease progression, when therapy is reintroduced and administered for another total of 8 individual cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first.

    Drug: Nivolumab

Interventions

  • FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks. Nivolumab: 240 mg flat dose; IV administration every 2 weeks.

    Also known as: Oxaliplatin, 5-fluorouracil, Leucovorin

  • DrugFLOX

    FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.

    Also known as: Oxaliplatin, 5-fluorouracil, Leucovorin

07

What researchers measure

Primary outcomes

  1. Primary - Progression-free Survival (PFS)

    To determine PFS, in terms of failure of treatment strategy, on sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen in previously untreated MSS mCRC. \*PFS: radiologic assessment every 8 weeks (following 4 cycles of FLOX or the alternative 2 cycles each of FLOX and nivolumab), according to the Response Evaluation Criteria in Solid Tumors (RECIST) and the RECIST consensus guideline for assessment of response to immune-modulating therapies (iRECIST), wherein complete response = disappearance of the lesion, partial response = at least a 30% decrease in the sum of diameters of target lesions, progressive disease = at least 20% increase in the sum of diameters of target lesions, and stable disease = no shrinkage or increase in size (per Watanabe H, Okada M, Kaji Y, et al. Gan To Kagaku Ryoho. 2009;36(13):2495-2501).

    Time frame: Through study completion (up to 37 months)

Secondary outcomes

  1. Secondary 1 - Incidence (Safety) and Grading (Tolerability) of Treatment-related Adverse Events

    To determine the number of participants (incidence; safety) with treatment-related adverse events and their grading (tolerability), as assessed by CTCAE v4.0, of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen. A lower adverse event score is better, where a score of 0 is best (no adverse event), 3 is severe, and 5 is death caused by the treatment. Stage 2 adverse events were not specifically reported unless related to hepatic toxicity events due to the potential effects of the drug on the patient (safety profile).

    Time frame: Through study completion (up to 37 months)

  2. Secondary 2 - Objective Response Rate (ORR)

    To determine the percentage of patients with confirmed complete or partial response of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen.

    Time frame: Through study completion (up to 37 months)

  3. Secondary 3 - Duration of Response (DOR)

    To determine the time from the first documentation of a complete or partial response to disease progression of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen.

    Time frame: Through study completion (up to 37 months)

  4. Secondary 4 - Secondary Curative Resection Rate (SSCRR)

    To determine the percentage of patients with a confirmed resection of metastatic disease with microscopically free margin (R0) of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen.

    Time frame: Through study completion (up to 37 months)

  5. Secondary 5 - Overall Survival (OS)

    To determine the time from randomization to death of any cause of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen.

    Time frame: Through study completion (up to 37 months)

  6. Secondary 6 - Quality-of-life (QoL)

    To monitor and compare QoL alterations during therapy courses using the consensus module EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life, 30 question version). The (patient-reported) EORTC-QLQ-C30 uses 5 functional scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea and vomiting), a global health status/quality of life scale and a number of other questions which assess items such as dyspnoea, loss of appetite, insomnia, constipation and diarrhoea, as well as the perceived financial impact of having cancer. Scales range from 0 to 100, and a higher score means a higher response rate, where a high score on the functional or global health status questions represents a high or healthy level of functioning, quality of life or, alternatively, more symptoms or issues (symptom scale/items). \[Scoring information summarised from the EORTC QLQ-C30 Scoring manual, 3rd edition\]

    Time frame: Through study completion (up to 37 months)

  7. Secondary 7 - Quality-of-life (QoL)

    To monitor and compare QoL alterations during therapy courses using the consensus module EORTC QLQ-CIPN20 (European Organisation for Research and Treatment of Cancer Quality of Life, 20 question Chemotherapy Induced Peripheral Neuropathy questionnaire). The EORTC QLQ-CIPN20 uses 20 questions assessing the quality of sensory, motor and autonomic symptoms on a 4-point Likert scale. Answers range from 1 (not at all) to 4 (very much). Patients indicate their perception of each item, and the scores are aggregated by quality, with a maximum of 32 points for motor, 36 for sensory, and either 12 (men) or 8 (women) in autonomic, where women would not answer a question about erectile function. Scores are then added together to give an overall score. The higher the score, the more symptoms the patient is experiencing.

    Time frame: Through study completion (up to 37 months)

  8. Secondary 8 - Quality-of-life (QoL)

    To monitor and compare QoL alterations during therapy courses using the consensus module EQ-5D-5L (EuroQoL's 5-dimension, 5-level questionnaire). The EQ-5D-5L questionnaire is a "standardised measure of health status developed by the EuroQol group to provide a simple, generic measure of health for clinical and economic appraisal". The questionnaire uses 5 dimensions (5D) - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. There are 5 response levels: no issues, slight problems, moderate problems, severe problems and unable to function/extreme problems. These answers are geared appropriately to the specific question being asked. Responses are coded from 0 for no problems to 5 for unable to function, and are combined to give a 5-digit code that will describe the patient's state of health. For example, 21111 would mean slight problems with mobility, but no other issues in the other dimensions. (summarised from the EQ-5D-5L user guide, v3.0).

    Time frame: Through study completion (up to 37 months)

Other outcomes

  1. Tertiary - Cost Estimate

    To compare costs for the resource use (in diagnostic work-up, treatment, and any adverse events) for the sequential therapy with that of the standard-of-care, applying a model specifically developed for CRC.

    Time frame: Through study completion (up to 37 months)

  2. Exploratory 1 - Circulating Biomarkers of Cytotoxic T Lymphocyte Activity

    To monitor the individual patients' levels of PTEN (phosphatase and tensin homolog) phosphatase activity in peripheral blood mononuclear cells throughout study treatment.

    Time frame: Through study completion (up to 37 months)

  3. Exploratory 2 - Circulating Biomarkers of Tumor Response

    To monitor the individual patients' levels of plasma tumor DNA throughout study treatment. Measure is variant allele frequency (VAF, in %) relative to baseline.

    Time frame: Through study completion (maximum of 37 months)

  4. Exploratory 3 - Circulating Biomarkers of Immune Cell Death (ICD)

    Measures of circulating immune factors and T cell phenotypes in serial serum/plasma/whole blood samples collected corresponding to each change of therapy in the sequential regimen.

    Time frame: Through study completion (maximum of 37 months)

  5. Exploratory 4 - Functional MR (Magnetic Resonance) Imaging Biomarkers

    To monitor the individual patients' changes in liver/peritoneal functional MR signals throughout study treatment. The COVID pandemic stopped the collection of data for this trial due to lack of available staff and equipment, as well as analysts. Therefore, no data will be presented for this outcome.

    Time frame: Through study completion (up to 37 months)

  6. Exploratory 5 - Histologic and Molecular Tumor Biomarkers

    To monitor the individual patients' changes in liver/peritoneal tissue composition throughout study treatment.

    Time frame: Through study completion (month 37)

08

Results

Posted Feb 13, 2026
Limitations and caveats
COVID affected the collection of samples and testing regimen due to lack of available staff, distancing regulations, etc.

Participant flow

Participant flow — Overall Study
MilestoneControl ArmExperimental Arm
Started3838
Completed3838
Not completed00

Outcome measures

PrimaryPrimary - Progression-free Survival (PFS)

To determine PFS, in terms of failure of treatment strategy, on sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen in previously untreated MSS mCRC. \*PFS: radiologic assessment every 8 weeks (following 4 cycles of FLOX or the alternative 2 cycles each of FLOX and nivolumab), according to the Response Evaluation Criteria in Solid Tumors (RECIST) and the RECIST consensus guideline for assessment of response to immune-modulating therapies (iRECIST), wherein complete response = disappearance of the lesion, partial response = at least a 30% decrease in the sum of diameters of target lesions, progressive disease = at least 20% increase in the sum of diameters of target lesions, and stable disease = no shrinkage or increase in size (per Watanabe H, Okada M, Kaji Y, et al. Gan To Kagaku Ryoho. 2009;36(13):2495-2501).

Time frame:
Through study completion (up to 37 months)
Reported as:
Median · Months of progression-free survival
Primary - Progression-free Survival (PFS)
Months of progression-free survivalControl ArmExperimental Arm
Primary - Progression-free Survival (PFS)9.2 (6.3 to 12.7)9.2 (4.5 to 15.0)
SecondarySecondary 1 - Incidence (Safety) and Grading (Tolerability) of Treatment-related Adverse Events

To determine the number of participants (incidence; safety) with treatment-related adverse events and their grading (tolerability), as assessed by CTCAE v4.0, of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen. A lower adverse event score is better, where a score of 0 is best (no adverse event), 3 is severe, and 5 is death caused by the treatment. Stage 2 adverse events were not specifically reported unless related to hepatic toxicity events due to the potential effects of the drug on the patient (safety profile).

Time frame:
Through study completion (up to 37 months)
Reported as:
Number · participants showing an adverse event
Secondary 1 - Incidence (Safety) and Grading (Tolerability) of Treatment-related Adverse Events
participants showing an adverse eventControl ArmExperimental Arm
Patients displaying a Grade 2 Adverse Event02
Patients displaying a Grade 3 Adverse Event2637
Patients displaying a Grade 4 Adverse Event1011
SecondarySecondary 2 - Objective Response Rate (ORR)

To determine the percentage of patients with confirmed complete or partial response of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen.

Time frame:
Through study completion (up to 37 months)
Reported as:
Count of participants · Participants
Secondary 2 - Objective Response Rate (ORR)
ParticipantsControl ArmExperimental Arm
Secondary 2 - Objective Response Rate (ORR)2017
SecondarySecondary 3 - Duration of Response (DOR)

To determine the time from the first documentation of a complete or partial response to disease progression of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen.

Time frame:
Through study completion (up to 37 months)
Reported as:
Median · Months with durable response
Secondary 3 - Duration of Response (DOR)
Months with durable responseControl ArmExperimental Arm
Secondary 3 - Duration of Response (DOR)9.0 (2.0 to 11.0)15.0 (7.0 to 18.0)
SecondarySecondary 4 - Secondary Curative Resection Rate (SSCRR)

To determine the percentage of patients with a confirmed resection of metastatic disease with microscopically free margin (R0) of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen.

Time frame:
Through study completion (up to 37 months)
Reported as:
Count of participants · Participants
Secondary 4 - Secondary Curative Resection Rate (SSCRR)
ParticipantsControl ArmExperimental Arm
Secondary 4 - Secondary Curative Resection Rate (SSCRR)51
SecondarySecondary 5 - Overall Survival (OS)

To determine the time from randomization to death of any cause of sequential treatment with the Nordic FLOX regimen and nivolumab compared with the standard-of-care Nordic FLOX regimen.

Time frame:
Through study completion (up to 37 months)
Reported as:
Median · Months
Secondary 5 - Overall Survival (OS)
MonthsControl ArmExperimental Arm
Secondary 5 - Overall Survival (OS)14.6 (10.6 to 23.2)20.7 (15.9 to 24.9)
SecondarySecondary 6 - Quality-of-life (QoL)

To monitor and compare QoL alterations during therapy courses using the consensus module EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life, 30 question version). The (patient-reported) EORTC-QLQ-C30 uses 5 functional scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea and vomiting), a global health status/quality of life scale and a number of other questions which assess items such as dyspnoea, loss of appetite, insomnia, constipation and diarrhoea, as well as the perceived financial impact of having cancer. Scales range from 0 to 100, and a higher score means a higher response rate, where a high score on the functional or global health status questions represents a high or healthy level of functioning, quality of life or, alternatively, more symptoms or issues (symptom scale/items). \[Scoring information summarised from the EORTC QLQ-C30 Scoring manual, 3rd edition\]

Time frame:
Through study completion (up to 37 months)

Results for this outcome have not been posted.

SecondarySecondary 7 - Quality-of-life (QoL)

To monitor and compare QoL alterations during therapy courses using the consensus module EORTC QLQ-CIPN20 (European Organisation for Research and Treatment of Cancer Quality of Life, 20 question Chemotherapy Induced Peripheral Neuropathy questionnaire). The EORTC QLQ-CIPN20 uses 20 questions assessing the quality of sensory, motor and autonomic symptoms on a 4-point Likert scale. Answers range from 1 (not at all) to 4 (very much). Patients indicate their perception of each item, and the scores are aggregated by quality, with a maximum of 32 points for motor, 36 for sensory, and either 12 (men) or 8 (women) in autonomic, where women would not answer a question about erectile function. Scores are then added together to give an overall score. The higher the score, the more symptoms the patient is experiencing.

Time frame:
Through study completion (up to 37 months)

Results for this outcome have not been posted.

SecondarySecondary 8 - Quality-of-life (QoL)

To monitor and compare QoL alterations during therapy courses using the consensus module EQ-5D-5L (EuroQoL's 5-dimension, 5-level questionnaire). The EQ-5D-5L questionnaire is a "standardised measure of health status developed by the EuroQol group to provide a simple, generic measure of health for clinical and economic appraisal". The questionnaire uses 5 dimensions (5D) - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. There are 5 response levels: no issues, slight problems, moderate problems, severe problems and unable to function/extreme problems. These answers are geared appropriately to the specific question being asked. Responses are coded from 0 for no problems to 5 for unable to function, and are combined to give a 5-digit code that will describe the patient's state of health. For example, 21111 would mean slight problems with mobility, but no other issues in the other dimensions. (summarised from the EQ-5D-5L user guide, v3.0).

Time frame:
Through study completion (up to 37 months)

Results for this outcome have not been posted.

Other pre-specifiedTertiary - Cost Estimate

To compare costs for the resource use (in diagnostic work-up, treatment, and any adverse events) for the sequential therapy with that of the standard-of-care, applying a model specifically developed for CRC.

Time frame:
Through study completion (up to 37 months)

Results for this outcome have not been posted.

Other pre-specifiedExploratory 1 - Circulating Biomarkers of Cytotoxic T Lymphocyte Activity

To monitor the individual patients' levels of PTEN (phosphatase and tensin homolog) phosphatase activity in peripheral blood mononuclear cells throughout study treatment.

Time frame:
Through study completion (up to 37 months)

No measurements were reported for this outcome.

Other pre-specifiedExploratory 2 - Circulating Biomarkers of Tumor Response

To monitor the individual patients' levels of plasma tumor DNA throughout study treatment. Measure is variant allele frequency (VAF, in %) relative to baseline.

Time frame:
Through study completion (maximum of 37 months)
Reported as:
Mean · Variant Allele Frequency (VAF, in %)
Exploratory 2 - Circulating Biomarkers of Tumor Response
Variant Allele Frequency (VAF, in %)Control ArmExperimental Arm
Baseline Visit (Time of Inclusion, before start of treatment)77.8 (0 to 100)66.7 (0 to 100)
1 Month after first treatment92.5 (0 to 221.9)2.3 (0 to 6.8)
2 months after first treatment97.9 (0 to 400.5)0.6 (0 to 1.75)
3 months after first treatment46.2 (0 to 110.4)1.7 (0 to 5.23)
4 months after first treatment46.2 (4 to 100)3.7 (0 to 8.1)
6 months after first treatment—8.0 (0 to 24)
8 months after first treatment—0.9 (0 to 2.56)
10 months after first treatment—0 (0 to 0)
12 months after first treatment—0.0 (0.0 to 0.0)
14 months after first treatment—3.6 (0.0 to 10.9)
16 months after first treatment—0.0 (0.0 to 0.0)
18 months after first treatment—0.0 (0.0 to 0.0)
20 months after first treatment—1.4 (0 to 4.2)
22 months after first treatment—15.7 (0.0 to 31.4)
23 months after first treatment—1.5 (0.0 to 2.9)
24 months after first treatment—20.3 (0.0 to 41)
25 months after first treatment—0.0 (0.0 to 0.0)
26 months after first treatment—0.0 (0.0 to 0.0)
28 months after first treatment—0.2 (0.2 to 0.2)
29 months after first treatment—3.5 (3.5 to 3.5)
30 months after first treatment—1.1 (1.1 to 1.1)
Other pre-specifiedExploratory 3 - Circulating Biomarkers of Immune Cell Death (ICD)

Measures of circulating immune factors and T cell phenotypes in serial serum/plasma/whole blood samples collected corresponding to each change of therapy in the sequential regimen.

Time frame:
Through study completion (maximum of 37 months)

Results for this outcome have not been posted.

Other pre-specifiedExploratory 4 - Functional MR (Magnetic Resonance) Imaging Biomarkers

To monitor the individual patients' changes in liver/peritoneal functional MR signals throughout study treatment. The COVID pandemic stopped the collection of data for this trial due to lack of available staff and equipment, as well as analysts. Therefore, no data will be presented for this outcome.

Time frame:
Through study completion (up to 37 months)

Results for this outcome have not been posted.

Other pre-specifiedExploratory 5 - Histologic and Molecular Tumor Biomarkers

To monitor the individual patients' changes in liver/peritoneal tissue composition throughout study treatment.

Time frame:
Through study completion (month 37)
Reported as:
Number · Number of T-cell receptor sequences
Exploratory 5 - Histologic and Molecular Tumor Biomarkers
Number of T-cell receptor sequencesExperimental Arm
At Baseline (Apr 2019)22185
At time of 1st relapse surgery (Jan 2021)82263
At time of 2nd relapse surgery (Nov 2021)7252

Adverse events

Collected over All patients were monitored for any adverse events throughout the trial and for 1 year after study completion (up to 37 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control Arm33/38 (86.8%)35/38 (92.1%)0/38 (0%)
Experimental Arm34/38 (89.5%)32/38 (84.2%)2/38 (5.3%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventControl ArmExperimental Arm
NeutropeniaBlood and lymphatic system disorders22/3815/38
Febrile neutropeniaBlood and lymphatic system disorders1/387/38
Venous thromboembolismBlood and lymphatic system disorders4/387/38
InfectionInfections and infestations5/385/38
FatigueNervous system disorders4/383/38
HyperglycaemiaImmune system disorders0/384/38
Increased hepatic enzymesImmune system disorders0/384/38
DiarrheaGastrointestinal disorders1/383/38
IleusGastrointestinal disorders3/383/38
RashImmune system disorders0/383/38
Most frequent other events
Most frequent other events
EventControl ArmExperimental Arm
Hepatobiliary disorders - Other, Increased hepatic enzymesHepatobiliary disorders0/382/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)Control ArmExperimental ArmTotal
Median65.0 (38 to 79)60.5 (43 to 80)64.5 (38 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Control ArmExperimental ArmTotal
Female152035
Male231841
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Control ArmExperimental ArmTotal
Count of participants——0
09

Study locations

5 sites
  • Haukeland University Hospital
    Bergen, 5021, Norway
  • Hospital of Southern Norway, Department of Oncology
    Kristiansand, 4604, Norway
  • Oslo University Hospital
    Oslo, 0424, Norway
  • Akershus University Hospital
    Oslo, 1478, Norway
  • St Olav's Hospital - Trondheim University Hospital
    Trondheim, 7006, Norway
10

References and documents

Publications

  • Dueland S, Ree AH, Groholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K. Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome. Clin Oncol (R Coll Radiol). 2016 Aug;28(8):532-9. doi: 10.1016/j.clon.2016.01.014. Epub 2016 Feb 14. PubMed 26888115 ↗
  • Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH. Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity? Radiother Oncol. 2016 Jun;119(3):505-11. doi: 10.1016/j.radonc.2016.02.020. Epub 2016 Mar 8. PubMed 26968754 ↗
  • Grovik E, Redalen KR, Storas TH, Negard A, Holmedal SH, Ree AH, Meltzer S, Bjornerud A, Gjesdal KI. Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor Ktrans and DeltaR2* peak are significantly associated with lymph node metastasis. J Magn Reson Imaging. 2017 Jul;46(1):194-206. doi: 10.1002/jmri.25566. Epub 2016 Dec 21. PubMed 28001320 ↗
  • Joranger P, Nesbakken A, Hoff G, Sorbye H, Oshaug A, Aas E. Modeling and validating the cost and clinical pathway of colorectal cancer. Med Decis Making. 2015 Feb;35(2):255-65. doi: 10.1177/0272989X14544749. Epub 2014 Jul 29. PubMed 25073464 ↗
  • Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH. Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening. BMC Cancer. 2016 Jul 26;16:536. doi: 10.1186/s12885-016-2601-x. PubMed 27461255 ↗
  • Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH. Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. Oncotarget. 2016 Jun 7;7(23):34907-17. doi: 10.18632/oncotarget.8995. PubMed 27145458 ↗
  • Ostrup O, Dagenborg VJ, Rodland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland AA, Maelandsmo GM, Borresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K. Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29. PubMed 29100312 ↗
  • Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR. Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies. Crit Rev Oncol Hematol. 2015 Jul;95(1):114-24. doi: 10.1016/j.critrevonc.2015.01.003. Epub 2015 Jan 12. PubMed 25624177 ↗
  • Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Ostrup O, Hovig E, Nygaard V, Rodland EA, Nakken S, Oien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Florenes VA, Hagene KT, Aas E, Luras H, Johnsen-Soriano S, Geitvik GA, Lingjaerde OC, Borresen-Dale AL, Maelandsmo GM, Flatmark K. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017. PubMed 28761742 ↗
  • Spindler KG, Boysen AK, Pallisgard N, Johansen JS, Tabernero J, Sorensen MM, Jensen BV, Hansen TF, Sefrioui D, Andersen RF, Brandslund I, Jakobsen A. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Oncologist. 2017 Sep;22(9):1049-1055. doi: 10.1634/theoncologist.2016-0178. Epub 2017 Aug 4. PubMed 28778958 ↗
  • Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012 May 20;30(15):1755-62. doi: 10.1200/JCO.2011.38.0915. Epub 2012 Apr 2. PubMed 22473155 ↗
  • Ree AH, Hoye E, Esbensen Y, Beitnes AR, Negard A, Bernklev L, Tetlie LK, Fretland AA, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Nilsen HL, Flatmark K, Meltzer S. Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade. Oncoimmunology. 2024 Jun 28;13(1):2372886. doi: 10.1080/2162402X.2024.2372886. eCollection 2024. PubMed 38952672 ↗
  • Ree AH, Saltyte Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Johansen C, Negard A, Bjornetro T, Nilsen HL, Berg JP, Flatmark K, Meltzer S. First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial. Br J Cancer. 2024 Jun;130(12):1921-1928. doi: 10.1038/s41416-024-02696-6. Epub 2024 Apr 25. PubMed 38664577 ↗
  • Meltzer S, Negard A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH. Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. Br J Cancer. 2022 Dec;127(12):2227-2233. doi: 10.1038/s41416-022-02004-0. Epub 2022 Oct 13. PubMed 36229579 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No plan to share unrandomised, individual participant data with any researchers not involved in the study at the outset.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Mar 2024, 69 months.

Results were first posted in Feb 2026, 1 year 10 months after primary completion.

Of 355 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's 69 months is above that.

Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2017
First posted
Jan 2, 2018
StartActual
May 29, 2018
Primary completionActual
Mar 18, 2024
CompletionActual
Mar 18, 2024
Results first posted
Feb 13, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03388190
Collaborators
Trondheim University Hospital, Haukeland University Hospital, Hospital of Southern Norway Trust, Oslo University Hospital
Responsible party
Prof Dr Anne Hansen Ree (Professor, MD PhD, University Hospital, Akershus) — Principal investigator
First posted
Jan 2, 2018
Start date
May 29, 2018
Primary completion
Mar 18, 2024
Completion
Mar 18, 2024
Results posted
Feb 13, 2026
Last update
Feb 13, 2026

Study contacts

Anne H Ree, MD PhD
principal investigator · University Hospital, Akershus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion